A world-first trial of ‘game-changer’ drug.
A ‘game-changer’ mRNA skin cancer jab is being tested on patients in the UK.
The jab is personalised for each patient, and could also help prevent ladder, lung and kidney cancer, if successful.
It works by telling the body to hunt down cancer cells and preventing the cancer from coming back.
A stage 2 trial involving pharmaceutical companies Moderna and MSD found it cut down the risk of the cancer returning in melanoma patients significantly.
University College London Hospitals NHS Foundation Trust (UCLH) is leading the phase 3 trial.